Canaccord raised the firm’s price target on Globus Medical (GMED) to $112 from $105 and keeps a Buy rating on the shares. The firm updatedits model to reflect its Q4 preliminary results while noting Nevro preliminary Q4/25 implied revenue was significantly above the firm’s $88.8M estimate, coming in at $99.9M.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Video: Defense stocks boosted by Trump budget request
- Globus Medical price target raised to $115 from $90 at Piper Sandler
- Globus Medical: Strong Execution and Upside Revisions Balanced by Full Valuation Support Hold Rating
- Globus Medical: Strong Fundamentals and Outperformance Largely Priced In, Justifying a Hold Rating
- Closing Bell Movers: Defense stocks surge on Trump military budget comments